Sign In
Buy RSLS
$3.92
+0 (+0%)
At Close: Nov 13, 2025
Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation
10:13am, Wednesday, 05'th Nov 2025
“From 2019 to 2025, the biomarker landscape has seen a surge in strategic collaborations, licensing, and acquisitions, driven by the growing demand for precision medicine, companion diagnostics, and
Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow
07:18pm, Thursday, 14'th Aug 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Therapeutics, Inc. (“Vyome”), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets wi
Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND
11:50am, Wednesday, 13'th Aug 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large marke
Vyome Announces New Board of Directors with Deep MIT and AI Ties
09:48am, Tuesday, 12'th Aug 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potentia
ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics
05:01pm, Thursday, 07'th Aug 2025
IRVINE, Calif.--(BUSINESS WIRE)---- $HIND--ReShape Lifesciences® (Nasdaq: RSLS) announced today that its shareholders have approved all of the proposals necessary to complete the previously announced
ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders
04:39pm, Thursday, 24'th Jul 2025
Partial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal; All Other Proposals Required for Merger Were Approved
ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit
08:31am, Tuesday, 22'nd Jul 2025
Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025 Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025
ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025
02:10pm, Monday, 21'st Jul 2025
Board of Directors Unanimously Recommend Approving Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System
08:31am, Tuesday, 01'st Jul 2025
Patent Enhances and Broadens the Company's Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device Patent Enhances and Broadens the Company's Intellectual Property Port
ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement
09:01am, Friday, 27'th Jun 2025
IRVINE, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on June 2
Reduction in Force Estimated to Save Over $750K or 23.4% of Annual Payroll Expenses Agreements Progress Toward Completion; Shareholder Meeting Scheduled for July 24, 2025 IRVINE, Calif., June 26, 2025
ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology
08:31am, Wednesday, 25'th Jun 2025
Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia
ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets
08:25am, Thursday, 12'th Jun 2025
Recon Supply Named Exclusive U.S. Distributor of ReShape's STIMEL-03, Lap-Band® 2.0 FLEX, and Full Product Portfolio to Reach U.S. Veterans and Active-Duty Service Members Recon Supply Named Exclusiv
ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering
09:00am, Monday, 09'th Jun 2025
IRVINE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (“ReShape” or the “Company”) (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions c
ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio
08:31am, Tuesday, 03'rd Jun 2025
IRVINE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Quality
